Literature DB >> 21674476

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Paul V Beum1, Margaret A Lindorfer, Elizabeth M Peek, P Todd Stukenberg, Michel de Weers, Frank J Beurskens, Paul W H I Parren, Jan G J van de Winkel, Ronald P Taylor.   

Abstract

We have reported that during complement-mediated cytolysis of B cells promoted by the CD20 mAbs rituximab or ofatumumab (OFA), long, thin structures that we call streamers (≥ 3 cell diameters) are rapidly generated and grow out from the cell surface. Streamers appear before cells are killed and contain opsonizing mAbs and membrane lipids. By exploiting the differential Ca(2+) requirements of discrete steps in the complement cascade, we determined that mAb-opsonized cells first tagged with C3b using C5-depleted serum are killed on addition of serum and EDTA, but the cells do not produce streamers. Also, cells first opsonized with OFA are lysed in serum containing Mg-EGTA by the alternative complement pathway but streamers are not produced. These findings indicate that Ca(2+) influx is necessary for streamer formation. Other mAbs that promote complement-mediated cytolysis also induce streamers on target cells. Streamer-like structures called nanotubes have been reported in several cellular systems, and are thought to promote intercellular communication/signaling. We tested whether this signaling could influence the susceptibility of neighboring cells contacted by streamers to complement attack and found that complement-mediated cytolysis of OFA-opsonized cells increases the resistance of unopsonized indicator cell populations to subsequent lysis when these cells are exposed to OFA and complement.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674476     DOI: 10.1002/eji.201041204

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Authors:  Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

2.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

3.  Potential role of nanotubes in context of clinical treatments?

Authors:  Julia Ranzinger; Amin Rustom; Vedat Schwenger
Journal:  Commun Integr Biol       Date:  2013-01-01

4.  Lipid droplets as a novel cargo of tunnelling nanotubes in endothelial cells.

Authors:  Ksenia Astanina; Marcus Koch; Christian Jüngst; Andreas Zumbusch; Alexandra K Kiemer
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

Review 5.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

6.  Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.

Authors:  Vijay Singh; Damodar Gupta; Alexandru Almasan
Journal:  J Cancer Sci Ther       Date:  2015-11-24

Review 7.  Emerging drugs and combinations to treat multiple myeloma.

Authors:  Alessandra Larocca; Roberto Mina; Francesca Gay; Sara Bringhen; Mario Boccadoro
Journal:  Oncotarget       Date:  2017-07-15

8.  Mechanisms of action of CD20 antibodies.

Authors:  Peter Boross; Jeanette H W Leusen
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma.

Authors:  Kai Wang; Yu Jiang; Weiyan Zheng; Zhiyong Liu; Hui Li; Jianzhou Lou; Meidi Gu; Xiaojian Wang
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

Review 10.  Tunneling nanotubes: Diversity in morphology and structure.

Authors:  Magnus Wiger Austefjord; Hans-Hermann Gerdes; Xiang Wang
Journal:  Commun Integr Biol       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.